A balloon catheter that includes an elongated main body, a balloon connected to the elongated main body, and a base layer on the outer surface of the balloon. The base layer includes a water-soluble low-molecular weight compound. The balloon catheter also includes a plurality of elongate bodies extending radially away from the outer surface of the balloon. The elongate bodies are crystals of a water-insoluble drug. The elongate bodies each possesses an independent longitudinal axis. At least part of at least some of the elongate bodies are located in the interior of the base layer on the outer surface of the balloon.

A balloon catheter that includes an elongated main body extending in an axial direction and a balloon connected to the distal portion of the elongated main body. The balloon includes an interior and is inflatable and deflatable. The balloon catheter also includes a plurality of elongate bodies extending radially away from the outer surface of the balloon. The elongate bodies are crystals of a water-insoluble drug. The elongate bodies each possess an independent longitudinal axis. Each of the elongate bodies includes a base portion at the proximal end of the elongate body. A plurality of elongate body proximal portions extend radially inwardly from the base portion of each of the elongate bodies toward the interior of the balloon. The elongate body proximal portions are continuous extensions of the crystal of the water-insoluble drug.

A balloon catheter that includes an elongated main body extending in an axial direction and a balloon connected to the distal portion of the elongated main body. The balloon includes an interior and is inflatable and deflatable. The balloon catheter also includes a plurality of elongate bodies extending radially away from the outer surface of the balloon. The elongate bodies are crystals of a water-insoluble drug. The elongate bodies each possess an independent longitudinal axis. Each of the elongate bodies includes a base portion at the proximal end of the elongate body. A plurality of elongate body proximal portions extend radially inwardly from the base portion of each of the elongate bodies toward the interior of the balloon. The elongate body proximal portions are continuous extensions of the crystal of the water-insoluble drug.

Provided herein includes a process for forming drug crystals of narrow size distribution and desire dimensions and morphology, the process includes a recrystallization step followed by a resizing step.

Embodiments relate to methods of forming a halide perovskite crystal. The method involves dispersing a halide perovskite material exhibiting a perovskite crystallographic lattice into a solution. The solution can include amine and a volatile solvent. The method involves forming a metastable intermediate state via amine molecules inserting into the perovskite crystallographic lattice. The method involves transitioning the perovskite material to a photo-sensitive phase via escape of the amine molecules from the perovskite crystallographic lattice. The method involves transitioning the metastable intermediate state to a halide perovskite crystal film.

Embodiments relate to methods of forming a halide perovskite crystal. The method involves dispersing a halide perovskite material exhibiting a perovskite crystallographic lattice into a solution. The solution can include amine and a volatile solvent. The method involves forming a metastable intermediate state via amine molecules inserting into the perovskite crystallographic lattice. The method involves transitioning the perovskite material to a photo-sensitive phase via escape of the amine molecules from the perovskite crystallographic lattice. The method involves transitioning the metastable intermediate state to a halide perovskite crystal film.

A method of fabricating an ionic crystal includes providing a single crystal substrate of an ionic crystal material is provided. A patterned mask is applied over the single crystal substrate A growth solution is introduced over the single crystal substrate. The growth solution includes precursors for epitaxial growth of the ionic crystal material on the single crystal substrate such that epitaxial crystals grow over time through pattern openings in the patterned mask into a crystal structure with one or more morphologies.

A method of fabricating an ionic crystal includes providing a single crystal substrate of an ionic crystal material is provided. A patterned mask is applied over the single crystal substrate A growth solution is introduced over the single crystal substrate. The growth solution includes precursors for epitaxial growth of the ionic crystal material on the single crystal substrate such that epitaxial crystals grow over time through pattern openings in the patterned mask into a crystal structure with one or more morphologies.

This invention relates to a method of forming crystals of chemical molecules. The methods are effective even when only very small amounts of a compound are available and can be used to explore the experimental crystallisation space including screening for optimal crystallisation conditions such as for polymorphic phases, salts, solvates and co-crystals of chemical molecules and to provide single crystals for structural determination of unknown molecules by single crystal X-ray crystallography.

This invention relates to a method of forming crystals of chemical molecules. The methods are effective even when only very small amounts of a compound are available and can be used to explore the experimental crystallisation space including screening for optimal crystallisation conditions such as for polymorphic phases, salts, solvates and co-crystals of chemical molecules and to provide single crystals for structural determination of unknown molecules by single crystal X-ray crystallography.